The authors of this study also supported that FGF-21 resistance may inhibit any counterbalancing effects of FGF-21 changes not only in NAFLD, but also in obesity and T2DM, which is in accordance with our speculation above. This evidence concerns the gene FGF21 and metabolic dysfunction-associated steatotic liver disease.